Revolution (RVMD) PT Raised to $265 at UBS as Daraxonrasib Pricing Announced

August 28, 2026 7:16 AM

UBS analyst Michael Yee raised the price target on Revolution (NASDAQ: RVMD) to $265.00 (from $220.00) while maintaining a Buy ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found